Matthew D Marsden

List of Publications by Year
in descending order

33	1,236	331670 21	414414 32
papers	citations	h-index	g-index

33	33	33	1664
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Latency reversal plus natural killer cells diminish HIV reservoir in vivo. Nature Communications, 2022, 13, 121.	12.8	36
2	Contribution of Sex Differences to HIV Immunology, Pathogenesis, and Cure Approaches. Frontiers in Immunology, 2022, 13, .	4.8	5
3	Can macrophages form a latent reservoir of HIV?. Future Virology, 2021, 16, 75-77.	1.8	0
4	Pharmacological Activation of Non-canonical NF-Î¹B Signaling Activates Latent HIV-1 Reservoirs InÂVivo. Cell Reports Medicine, 2020, 1, 100037.	6.5	26
5	Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10688-10698.	7.1	34
6	Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy. Nature Communications, 2020, 11, 1879.	12.8	29
7	Benefits and limitations of humanized mice in HIV persistence studies. Retrovirology, 2020, 17, 7.	2.0	25
8	Tracking HIV Rebound following Latency Reversal Using Barcoded HIV. Cell Reports Medicine, 2020, 1, 100162.	6.5	11
9	Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1 ⁺ and TIGIT ⁺ CD4 T Cells. Journal of Virology, 2019, 93, .	3.4	21
10	HIV cure strategies: a complex approach for a complicated viral reservoir?. Future Virology, 2019, 14, 5-8.	1.8	11
11	Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology, 2018, 520, 83-93.	2.4	33
12	Humanized Mouse Models for Human Immunodeficiency Virus Infection. Annual Review of Virology, 2017, 4, 393-412.	6.7	65
13	In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication. PLoS Pathogens, 2017, 13, e1006575.	4.7	73
14	Disruption of Type I Interferon Induction by HIV Infection of T Cells. PLoS ONE, 2015, 10, e0137951.	2.5	18
15	Double Trouble: HIV Latency and CTL Escape. Cell Host and Microbe, 2015, 17, 141-142.	11.0	15
16	Studies of retroviral infection in humanized mice. Virology, 2015, 479-480, 297-309.	2.4	33
17	RNAi-Mediated CCR5 Knockdown Provides HIV-1 Resistance to Memory T Cells in Humanized BLT Mice. Molecular Therapy - Nucleic Acids, 2015, 4, e227.	5.1	28
18	Experimental Approaches for Eliminating Latent HIV. Forum on Immunopathological Diseases and Therapeutics, 2015, 6, 91-99.	0.1	16

#	Article	IF	Citations
19	Bioengineered Vaults: Self-Assembling Protein Shellâ€“Lipophilic Core Nanoparticles for Drug Delivery. ACS Nano, 2014, 8, 7723-7732.	14.6	54
20	Neutralizing the HIV Reservoir. Cell, 2014, 158, 971-972.	28.9	12
21	HIV/AIDS eradication. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4003-4010.	2.2	40
22	Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11698-11703.	7.1	130
23	HIV Latency in the Humanized BLT Mouse. Journal of Virology, 2012, 86, 339-347.	3.4	106
24	Virological Evidence Supporting the Use of Raltegravir in HIV Post-Exposure Prophylaxis Regimens. Antiviral Therapy, 2012, 17, 1375-1379.	1.0	4
25	Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nature Chemistry, 2012, 4, 705-710.	13.6	152
26	HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes. Virology, 2011, 417, 394-399.	2.4	8
27	Single Mutations in HIV Integrase Confer High-Level Resistance to Raltegravir in Primary Human Macrophages. Antimicrobial Agents and Chemotherapy, 2011, 55, 3696-3702.	3.2	23
28	Activation of Latent HIV Using Drug-Loaded Nanoparticles. PLoS ONE, 2011, 6, e18270.	2.5	80
29	Establishment and maintenance of HIV latency: model systems and opportunities for intervention. Future Virology, 2010, 5, 97-109.	1.8	26
30	Eradication of HIV: current challenges and new directions. Journal of Antimicrobial Chemotherapy, 2008, 63, 7-10.	3.0	55
31	Short Communication:Activating Stimuli Enhance Immunotoxin-Mediated Killing of HIV-Infected Macrophages. AIDS Research and Human Retroviruses, 2008, 24, 1399-1404.	1.1	10
32	Human Immunodeficiency Virus Bearing a Disrupted Central DNA Flap Is Pathogenic In Vivo. Journal of Virology, 2007, 81, 6146-6150.	3.4	26
33	Primary Cell Model for Activation-Inducible Human Immunodeficiency Virus. Journal of Virology, 2007, 81, 7424-7434.	3.4	31